This updated formulation is a bivalent vaccine that combines the original vaccine with vaccines targeting Omicron sublineages BA.4 and BA.5 and is administered at a dose of 50 micrograms.
Phase 2/3 clinical trials of these boosters are currently underway, according to the company. The data they submitted to the FDA are from experiments in mice and from humans using a different booster updated to protect against Omicron’s BA.1 strain.
“We have worked closely with the FDA to ensure that Americans have access to Moderna’s updated bivalent booster. “It has the potential to offer higher, wider and more durable protection against the elements,” said Stephan Bansel, CEO of Moderna.
The announcement comes a day after Pfizer and BioNTech announced they had submitted an application to the U.S. Food and Drug Administration for emergency use approval of a bivalent Covid-19 booster for use in people over the age of 12. It was broken.
When are shots available?
Dr. Ashish Jha, the White House’s Covid-19 response coordinator, recently said the updated booster is expected to be available to the public in early to mid-September, though it remains to be seen when the shots will be approved. It is up to the FDA to
FDA spokesperson Abigail Capobianco said in a statement emailed to CNN last week, “The FDA will use all available evidence to approve the bivalent booster for the fall.” We have data on millions of individuals who have received the prototype component as a booster: for the BA.4/5 component, nonclinical data obtained in mice, previous variant vaccines (including those to beta, delta) Extensive knowledge of the safety and efficacy of the mRNA platform, along with combined data from and omicron BA.1), will be used in this decision.”
According to data previously published by Moderna in June, the booster dose “induced strong neutralizing antibody responses to the Omicron subvariants BA.4 and BA.5 in all participants, regardless of previous infection.” .
The FDA will evaluate the Moderna data, but has not indicated whether it will convene vaccine advisors before making an approval decision. Such measures may be reversed when injections can be administered.
Production of updated shots is already underway. The U.S. government has purchased 105 million of his bivalent Covid-19 vaccine booster doses from Pfizer and another 66 million renewal shots from Moderna.
Source: www.cnn.com
